Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication (vol 19, 119, 2018)

被引：0
|
作者：
Winner, Paul K. [1 ]
Singh, Rashmi B. Halker [2 ]
Cohen, Joshua M. [3 ]
Yang, Ronghua [3 ]
Yeung, Paul P. [3 ]
Ramirez Campos, Verena [4 ]
机构：
[1] Premiere Res Inst, W Palm Beach, FL 33407 USA
[2] Mayo Clin, Phoenix, AZ USA
[3] Teva Pharmaceut, Frazer, PA USA
[4] Teva Pharmaceut, Buenos Aires, DF, Argentina
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Long-term impact of fremanezumab on response rate, acute headache medication use, and disability in episodic migraine patients with acute medication overuse at baseline: results of a 1-year study
    Lipton, Richard M.
    Turner, Ira
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Yang, Ronghua
    Ning, Xiaoping
    Elms, Shawn
    CEPHALALGIA, 2019, 39 : 247 - 248
  • [32] The impact of fremanezumab on medication overuse in patients with chronic migraine (vol 19, pg P12, 2018)
    Silberstein, Stephen D.
    Ashina, Sait
    Katsarava, Zaza
    Bibeau, Kristen
    Seminerio, Michael J.
    Harlow, Danielle E.
    Cohen, Joshua M.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [33] LONG-TERM EFFICACY OF FREMANEZUMAB IN MIGRAINE PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE MEDICATION CLASSES
    Naegel, Steffen
    Cohen, Joshua
    Campos, Verena Ramirez
    Barash, Steve
    Ning, Xiaoping
    Dhiraj, Dalbir
    Kudrow, David
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09)
  • [34] The impact of fremanezumab on symptoms associated with migraine in patients with episodic migraine (vol 19, pg P3, 2018)
    Brandes, Jan L.
    Yeung, Paul P.
    Aycardi, Ernesto
    Yang, Ronghua
    Ma, Yuju
    Cohen, Joshua M.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [35] INDIRECT COMPARISON OF THE EFFICACY OF FREMANEZUMAB VERSUS ERENUMAB IN EPISODIC MIGRAINE PATIENTS WHO HAD FAILED 2-4 PRIOR MIGRAINE PREVENTIVE TREATMENTS
    Patterson-Lomba, O.
    Thompson, S.
    Gandhi, S. K.
    Yang, R.
    Cohen, J.
    Mu, F.
    Young, J.
    VALUE IN HEALTH, 2019, 22 : S737 - S737
  • [36] Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response
    Buse, Dawn C.
    Krasenbaum, Lynda J.
    Seminerio, Michael J.
    Packnett, Elizabeth R.
    Carr, Karen
    Ortega, Mario
    Driessen, Maurice T.
    PAIN AND THERAPY, 2024, 13 (03) : 511 - 532
  • [37] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients With Chronic Migraine: Results of a 1-Year Study
    McAllister, Peter
    Yeung, Paul P.
    Cohen, Joshua
    Gandhi, Sanjay
    Yang, Ronghua
    NEUROLOGY, 2019, 92 (15)
  • [38] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine: Results of a 1-Year Study
    McAllister, P.
    Cohen, J. M.
    Gandhi, S. K.
    Yang, R.
    HEADACHE, 2019, 59 : 114 - 114
  • [39] Efficacy of Fremanezumab in Migraine Patients With Pain or Psychiatric Comorbidities and Documented Inadequate Response to 2-4 Prior Migraine Preventive Medication Classes
    Spierings, E. L. H.
    Ning, X.
    Cohen, J. M.
    Campos, V. Ramirez
    Barash, S.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1) : 18 - 18
  • [40] Efficacy of Fremanezumab in Migraine Patients With Pain or Psychiatric Comorbidities and Documented Inadequate Response to 2-4 Prior Migraine Preventive Medication Classes
    Spierings, E. L. H.
    Ning, X.
    Cohen, J. M.
    Campos, V. Ramirez
    Barash, S.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 26 - 27
12345